Impact of a Glaucoma Awareness Program on Treatment Adherence

ConditionGlaucoma

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorSeva Canada Society

About this trial

Glaucoma is a leading cause of irreversible blindness worldwide, with a higher burden in low- and middle-income countries such as Nepal, where public awareness and treatment adherence remain poor. Lifelong adherence to treatment is important to prevent disease progression but still non adherence remains common.

This is a mixed method study which aims to evaluate the effectiveness of structured glaucoma awareness program in improving treatment adherence among glaucoma patients attending a tertiary eye hospital in Nepal. Quantitative assessment will measure changes in treatment adherence using Medication Adherence Scale at baseline and three months post intervention. A qualitative component will explore participants' perceptions of glaucoma program and suggestions for improvement through semi-structured interviews.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged ≥18 years

Diagnosed with glaucoma

Attending follow-up at the study hospital

Able to provide informed consent

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

Glaucoma awareness and patient education program
Other intervention
Glaucoma awareness educational package: Educational session, information leaflets, interactive discussions. This study involves a behavioral/educational intervention only. No drugs, devices, or procedures are introduced as part of the study intervention. Participants continue their routine standard-of-care glaucoma treatment as prescribed by their treating ophthalmologist. No investigational drugs or devices are used as part of this study. Participants continue their usual prescribed anti-glaucoma medications as part of routine clinical care. The study intervention consists solely of a structured educational and awareness program.

Treatment groups

60 Participants

are divided into 1 treatment group

Group A: Glaucoma awarenessExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Treatment adherence scores

Treatment adherence will be assessed using Glaucoma Treatment Compliance Assessment Tool- Short Form(GTCAT-S). Treatment adherence will be assessed using the Glaucoma Treatment Compliance Assessment Tool-Short Form (GTCAT-S), a validated self-administered questionnaire designed to evaluate adherence behavior, beliefs, and barriers among glaucoma patients. Approval for the use of GTCAT-S in this study has been obtained from the GTCAT development team. Scale Details: * Each item is scored on a 5-point Likert scale: 1 = Disagree a lot to 5 = Agree a lot * Patients classified * Low adherence: \<75% * High adherence: ≥75% * Direction: Higher scores indicate better treatment adherence

Time frame

10 months

Secondary outcomes

Participants' perceptions of the glaucoma awareness program assessed using semi-structured interview guide

Participants' perceptions of the glaucoma awareness program, including perceived usefulness, clarity of information, behavioral impact, barriers to treatment adherence, and suggestions for improvement, will be assessed through semi-structured in-depth interviews conducted at three months post-intervention. Assessment Method: * Semi-structured interview guide developed by the research team * Open-ended questions exploring: * Understanding of glaucoma * Perceived benefits of the awareness program * Barriers to applying learned information * Suggestions for improving patient education * Interviews will be audio-recorded, transcribed verbatim, translated into English, and analyzed using thematic analysis Scale Used: Not applicable (qualitative assessment; no numerical scoring)

Time frame

3 months post-intervention

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Seva Canada Society

Lead sponsor

Reiyukai Eiko Masunaga Eye Hospital (REMEH)

Collaborator

Pragyaan Sustainable Health Outcomes Foundation